1. Home
  2. IMUX vs ASRT Comparison

IMUX vs ASRT Comparison

Compare IMUX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$14.08

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Logo Assertio Holdings Inc.

ASRT

Assertio Holdings Inc.

HOLD

Current Price

$23.49

Market Cap

76.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMUX
ASRT
Founded
2016
1995
Country
United States
United States
Employees
66
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.6M
76.0M
IPO Year
2013
2004

Fundamental Metrics

Financial Performance
Metric
IMUX
ASRT
Price
$14.08
$23.49
Analyst Decision
Strong Buy
Hold
Analyst Count
6
2
Target Price
$36.00
$18.00
AVG Volume (30 Days)
230.1K
306.8K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
38.00
N/A
EPS
N/A
N/A
Revenue
N/A
$118,713,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$0.61
52 Week High
$15.77
$23.49

Technical Indicators

Market Signals
Indicator
IMUX
ASRT
Relative Strength Index (RSI) 62.69 83.19
Support Level $0.74 $11.05
Resistance Level $15.77 N/A
Average True Range (ATR) 1.37 0.03
MACD -0.41 -0.20
Stochastic Oscillator 60.31 86.96

Price Performance

Historical Comparison
IMUX
ASRT

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: